Activity Description & Educational Objectives
In this activity, experts in gastroenterology discuss the management of patients with inflammatory bowel disease.
Upon completion of this activity, participants should be better able to:
- Evaluate clinical trial data focused on the efficacy and safety of current and emerging therapeutic options for inflammatory bowel disease (IBD)
- Apply the latest clinical findings surrounding the appropriate selection, clinical use, and monitoring of pharmacologic therapies in patients with IBD
- Discuss practical strategies to overcome current challenges in the clinical management of patients with IBD
This activity has been designed to meet the educational needs of gastroenterologists and other clinicians involved in the management of patients with inflammatory bowel disease.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: November 27, 2013 - November 26, 2014
Time to Complete: 45 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
William J. Sandborn, MD
Chief, Division of Gastroenterology
Professor of Medicine and Adjunct Professor of Surgery
University of California San Diego
La Jolla, California
William J. Sandborn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Amgen Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Santarus Inc.; Shire; Takeda Pharmaceutical Company Limited; UCB, Inc.; and Warner Chilcott.
Grant/Research Support from Amgen Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.
Speakers Bureau participant with AbbVie Inc.
Adam Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Adam Cheifetz, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Pfizer Inc.
Advisory Board for AbbVie and Janssen Pharmaceuticals, Inc.
David G. Binion, MD
Co-Director, IBD Center
Director, Nutrition Support Service
UPMC Presbyterian Hospital
Professor of Medicine
University of Pittsburgh School of Medicine
David G. Binion, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for UCB, Inc.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education
Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5480-14-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by independent educational grants from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.